Joshua Freedman Email & Phone Number | Biologics scientific lead with over 10 years of expertise turning unmet clinical need into drug candidates. Most recently, I was the program lead on Adaptate's principal drug program contributing to a successful acquisition and co-leading a successful integration of the Adaptate R&D team into Takeda Pharmaceuticals (Boston). Experienced in immunology, cancer biology and gene therapy across industry, biotechnology and academia. My academic background is in biochemistry and immuno-oncology (B.A. & M.Sc, University of Cambridge; PhD, University of Oxford), with doctoral research focused on engineering novel adenovirus-based therapeutics aimed at 'reinvigorating' tumour-infiltrating T cells. This research led to the initiation of a Phase I clinical trial, five peer-reviewed publications in high-impact journals, a patent filing and the top conference award for outstanding research. Proven record of leading industry teams to advance biologics with novel mechanisms of action (MOAs) from discovery through preclinical development to positive regulatory engagements and IND, both as a Discovery Lead and Preclinical Lead. Effectively built multiple multi-disciplinary teams to deliver on end-to-end preclinical strategy and an expert in leading the science behind tumour-targeted antibodies, multi-specific engagers and adenoviral gene therapies.

Joshua Freedman

Biologics scientific lead with over 10 years of expertise turning unmet clinical need into drug cand...
London, England, United Kingdom

*50 free lookup(s) per month.

Joshua Freedman’s Email joshf@takeda.com

Joshua Freedman’s Phone Numbers

Get JOSHUA’s Phone Number (For Free)

Social Media

Joshua Freedman’s Location London, England, United Kingdom

Joshua Freedman’s Current Industry Takeda

Joshua Freedman’s Prior Industry Adaptate Biotherapeutics | Kings College London | Theolytics | University Of Oxford

Find accurate emails & phone numbers for over 700M professionals.

Program Lead, Preclinical (Principal Scientist)

2022-04-01 00:00:00 - Present

Program Lead, Preclinical (Principal Scientist/Senior Scientist)

2020-04-01 00:00:00 - 2022-04-01 00:00:00

Research Associate (Adrian Hayday Lab)

2020-04-01 00:00:00 - 2020-05-01 00:00:00

Team Lead, Discovery (Senior Scientist/Scientist)

2017-10-01 00:00:00 - 2020-04-01 00:00:00

Graduate Scientist (Research Associate/PhD/Postdoc)

2013-01-01 00:00:00 - 2017-08-01 00:00:00

No Skills Available

No Languages Available

Joshua Freedman is a Biologics scientific lead with over 10 years of expertise turning unmet clinical need into drug candidates. Most recently, I was the program lead on Adaptate's principal drug program contributing to a successful acquisition and co-leading a successful integration of the Adaptate R&D team into Takeda Pharmaceuticals (Boston). Experienced in immunology, cancer biology and gene therapy across industry, biotechnology and academia. My academic background is in biochemistry and immuno-oncology (B.A. & M.Sc, University of Cambridge; PhD, University of Oxford), with doctoral research focused on engineering novel adenovirus-based therapeutics aimed at 'reinvigorating' tumour-infiltrating T cells. This research led to the initiation of a Phase I clinical trial, five peer-reviewed publications in high-impact journals, a patent filing and the top conference award for outstanding research. Proven record of leading industry teams to advance biologics with novel mechanisms of action (MOAs) from discovery through preclinical development to positive regulatory engagements and IND, both as a Discovery Lead and Preclinical Lead. Effectively built multiple multi-disciplinary teams to deliver on end-to-end preclinical strategy and an expert in leading the science behind tumour-targeted antibodies, multi-specific engagers and adenoviral gene therapies.

Joshua Freedman has prior
experience in the following industries:
Adaptate Biotherapeutics | Kings College London | Theolytics | University Of Oxford

Joshua Freedman has the following professional experience:
Takeda | Adaptate Biotherapeutics | Kings College London | Theolytics | University Of Oxford